RecruitingNCT03838718

REtroperitoneal SArcoma Registry: an International Prospective Initiative

REtroperitoneal SArcoma Registry (RESAR): Prospective Collection of Primary Retroperitoneal Sarcoma Patient's Data, Radiological and Pathological Material for the TransAtlantic Retroperitoneal Sarcoma Working Group

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Enrollment

2,000 participants

Start Date

Sep 1, 2016

Study Type

OBSERVATIONAL

Conditions

Retroperitoneal Sarcoma

Summary

Surgery is currently the only potentially curative treatment modality for localized retroperitoneal sarcoma (RPS). Available studies regarding oncologic outcomes are mainly retrospective in nature, and RPS are recognized as a rare disease. Therefore, prospective analysis of high quality data is a top priority. Primary Objectives of this study are: * to prospectively collect standardized clinical data and radiological and pathological material from primary RPS patients treated with surgery at reference centers. * patient outcome will be evaluated in terms of overall survival (OS), disease-free survival (DFS), crude cumulative incidence (CCI) of local recurrence (LR) and distant metastasis (DM). Secondary Objectives: * to estimate the efficacy and safety of surgical treatment, including extended surgical approach to primary RPS; * to prospectively evaluate the impact of multimodality therapy, including radiation therapy and chemotherapy; * to identify clinical, radiological and pathological characteristics that may influence the oncological outcome or may be used as predictors of LR/DM/OS. These may be important biomarkers of disease; * to utilize collected pathological material for research collaborations.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is building an international registry (a detailed database) to track patients who have been treated for a rare cancer called retroperitoneal sarcoma — a tumor that forms in the fat or muscle tissue at the back of the abdomen — in order to better understand outcomes and treatment patterns. **You may be eligible if...** - You have been newly diagnosed with a primary retroperitoneal sarcoma (a soft tissue cancer in the abdomen/back area) and had surgery at a participating hospital - You are older than 18 years at the time of your first treatment - Your diagnosis was confirmed by a specialist pathologist following WHO criteria - You had appropriate CT or MRI imaging before your surgery - You are willing to be followed up over the long term **You may NOT be eligible if...** - You are younger than 18 years old - Your cancer is a recurrence (it has come back after previous treatment) - Your tumor is benign (non-cancerous) - You have a severe psychiatric condition that prevents informed consent or follow-up - Adequate follow-up cannot be ensured at your treating center Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(22)

University of Southern California (USC)

Los Angeles, California, United States

Mayo Clinic

Jacksonville, Florida, United States

Moffitt Cancer Center

Tampa, Florida, United States

Winship Cancer Institute

Emory, Georgia, United States

Brigham and Women's Hospital/Dana-Farber Cancer Institute

Boston, Massachusetts, United States

The Ohio State University

Columbus, Ohio, United States

Peter MacCallum Cancer Center

Melbourne, Australia

Maisonneuve-Rosemont Hospital / University of Montreal

Montreal, Canada

The Ottawa Hospital

Ottawa, Canada

Mount Sinai / Princess Margaret

Toronto, Canada

Institut Curie

Paris, France

University Medical Center and Medical Faculty Mannheim, University of Heidelberg

Mannheim, Germany

Ludwig Maximilian University

Munich, Germany

Fondazione IRCCS Istituto Nazionale dei Tumori

Milan, Italy

Veneto Institute of Oncology

Padova, Italy

Ospedale Borgo Roma

Verona, Italy

Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology

Warsaw, Poland

Institute of Oncology Ljubljana

Ljubljana, Slovenia

Samsung Medical Center

Seoul, South Korea

Hospital Clinico Universitario "Virgen de la Arrixaca"

Murcia, Spain

University Hospital Birmingham (Queen Elizabeth)

Birmingham, United Kingdom

Royal Marsden Hospital

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT03838718

Related Trials

Electrochemotherapy (ECT) in Patients With Primary Visceral Tumors and/or Secondary Visceral Localizations, of Any Histotype

NCT067531361 location

Surgery With or Without Neoadjuvant Chemotherapy in High Risk RetroPeritoneal Sarcoma

NCT04031677164 locations

Evaluation of Abemaciclib and Radiation Therapy Before Surgery for the Treatment of High-Risk Adipocytic Retroperitoneal Sarcoma

NCT060257471 location

Proton or Photon RT for Retroperitoneal Sarcomas

NCT0165920310 locations

Precision Medicine Approaches for Neoadjuvant Therapy in High-risk Sarcoma Patients

NCT074329321 location